The Dawn of a New Era in the Treatment of Acute Myocardial Infarction. Meeting. Florence, ITA, 1999/01.
In the United States by mid-century, cardiovascular disease accounted for more than half of all deaths.
In the second half of this century, 85% of reduction in age-adjusted mortality rates from all causes can be ascribed to the decline in death from cardiovascular disease and stroke.
Approximately half of such dramatic decline in mortality rates from ischemic heart disease (IHD) can be explained by primary and secondary prevention and half by therapeutic improvements.
Epidemiology of therapeutic regimens in acute myocardial infarction (AMI) indicates substantial increases in the use of thrombolytic therapy, aspirin, bêta-blockers and, in some countries, coronary angioplasty.
The long-term results of several thrombolytic trials have shown the persistence of early benefit until 10 years after AMI.
However, approximately half of the patients with AMI are admitted to the hospital too late to fully benefit from thrombolytic therapy, and one fourth of eligible patients do not receive any form of reperfusion.
Primary angioplasty is advocated by some as the treatment of choice in AMI.
The present results are not convincing enough to induce the enormously complex and costly reorganization of the health system, allowing the immediate access to coronary angiography for all or most patients with AMI.
However, stenting the infarct coronary artery at the site of previous occlusion appears to improve the immediate and medium-term results of coronary revascularization procedures. (...)
Mots-clés Pascal : Infarctus, Myocarde, Homme, Epidémiologie, Appareil circulatoire pathologie, Cardiopathie coronaire, Myocarde pathologie
Mots-clés Pascal anglais : Infarct, Myocardium, Human, Epidemiology, Cardiovascular disease, Coronary heart disease, Myocardial disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0463261
Code Inist : 002B12A03. Création : 22/03/2000.